Methodological and practical challenges for personalized cancer therapies

[1]  T. Helbich,et al.  Molecular imaging of cancer: MR spectroscopy and beyond. , 2012, European journal of radiology.

[2]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[3]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[4]  Hisataka Kobayashi,et al.  Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. , 2011, Accounts of chemical research.

[5]  K. Ogawa,et al.  Radiosynthesis and Initial In Vitro Evaluation of [18F]F-PEG6-IPQA—A Novel PET Radiotracer for Imaging EGFR Expression-Activity in Lung Carcinomas , 2011, Molecular Imaging and Biology.

[6]  R. Harapanhalli.  Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals. , 2010, Seminars in nuclear medicine.

[7]  F. André,et al.  Molecular circuits of solid tumors: prognostic and predictive tools for bedside use , 2010, Nature Reviews Clinical Oncology.

[8]  Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. , 2010, Chemical reviews.

[9]  Frank McCormick,et al.  The molecular pathology of cancer , 2010, Nature Reviews Clinical Oncology.

[10]  M. Smith,et al.  Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. , 2010, European journal of cancer.

[11]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[12]  Gennady M Verkhivker,et al.  Cancer driver mutations in protein kinase genes. , 2009, Cancer letters.

[13]  A. Hagooly,et al.  Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer , 2009, Journal of Nuclear Medicine.

[14]  F. Kaye.  Mutation-associated fusion cancer genes in solid tumors , 2009, Molecular Cancer Therapeutics.

[15]  G. Giaccone,et al.  Next generation oncology drug development: opportunities and challenges , 2009, Nature Reviews Clinical Oncology.

[16]  Edward S. Kim,et al.  Molecular targets for cancer chemoprevention , 2009, Nature Reviews Drug Discovery.

[17]  Mary K Pendergast,et al.  Regulatory Agency Consideration of Pharmacogenomics , 2008, Experimental biology and medicine.

[18]  James R. Anderson,et al.  Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. , 2008, Seminars in oncology.

[19]  E. Diamandis,et al.  Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.

[20]  Edward S. Kim,et al.  Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine , 2008, Clinical trials.

[21]  J. Hoffman,et al.  Regulatory and reimbursement challenges for molecular imaging. , 2007, Radiology.

[22]  A. Alavi,et al.  Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.

[23]  Ian Collins,et al.  New approaches to molecular cancer therapeutics , 2006, Nature chemical biology.

[24]  C. Eilles,et al.  Clinical value of planar and tomographic dual-isotope scintigraphy using 99mTc-methylene diphosphonate and 131I in patients with thyroid cancer , 2006, Nuclear medicine communications.

[25]  N. Tomura,et al.  Comparison of201Tl-chloride SPECT with99mTc-MIBI SPECT in the depiction of malignant head and neck tumors , 2006 .

[26]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, , 2006 .

[27]  N. Tomura,et al.  Comparison of 201Tl-chloride SPECT with 99mtc-MIBI SPECT in the depiction of malignant head and neck tumors. , 2006, Annals of nuclear medicine.

[28]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[29]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[30]  Faculty Opinions recommendation of EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. , 2004 .

[31]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[32]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[33]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[34]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[35]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[36]  G. Heppner,et al.  Mutagenic activity of tumor-associated macrophages in Salmonella typhimurium strains TA98 and TA 100. , 1984, Cancer research.

[37]  G. Heppner.  Tumor heterogeneity. , 1984, Cancer research.

[38]  I. Fidler,et al.  Tumor heterogeneity and the biology of cancer invasion and metastasis. , 1978, Cancer research.